Document is current

Article History

Received: 15 November 2025

Accepted: 4 March 2026

First Online: 19 April 2026

Declarations

:

: This study was conducted in strict accordance with the principles of the Declaration of Helsinki and approved by the Ethics Review Committee of the Affiliated Hospital of Guizhou Medical University (Ethics Approval No.: GMU2024-452). All participants were patients aged 30–70 years who underwent thyroid resection at the Affiliated Hospital of Guizhou Medical University between November 2024 and August 2025, and were pathologically confirmed as PTC with no history of preoperative chemoradiotherapy, cognitive impairment, or other concomitant malignancies. Prior to tissue sampling, all participants (or their legally authorized representatives, if applicable) were provided with a detailed written explanation of the study purpose, procedures, potential risks, and the intended use of tissue samples (for experimental research on papillary thyroid cancer molecular mechanisms only, without involvement in commercial applications). Written informed consent was obtained from each participant to confirm their voluntary participation and agreement to the use of their de-identified tissue samples and clinical data (e.g., pathological stage, survival information) for this study. All tissue samples were anonymized by removing personal identifiers (e.g., name, hospital ID) immediately after collection, and stored and processed in compliance with the hospital’s ethical guidelines for biological sample management to protect participant privacy.

: The authors declare no competing interests.